Cardiol Therapeutics Inc.

NASDAQ:CRDL

Drug Manufacturers - Specialty & Generic

Healthcare
$0.95 -0.47%

-$0.01 today

Market cap
$114.64M
Beta
0.80
P/E (TTM)
-4.5
EPS (TTM)
-$0.33
52W Low $0.88High $1.71

Volume 0.31M

Average 0.68M

CRDL Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Cardiol Therapeutics Inc.NASDAQ: CRDL

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow growth accelerates

Q1 FY2026 free cash flow of CA$7.58M (cash outflow) rose 5.8% year over year, ahead of the -4.0% change in trailing-twelve-month free cash flow. Sequentially, it rose 45.1% from the prior quarter. Over 3 fiscal years it compounded at -4.4% a year.

Context

  • Free cash flow grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +5.8% holds above the trailing-twelve-month pace of -4.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$7.58M+45.1% QoQ
Last fiscal yearDec 2025
-CA$23.88M-4.8% YoY
LTMMar 2026
-CA$24.3M-4.0% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.8%——
1 year-4.8%——
3-year CAGR-4.4%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

CAD · from the cash flow

Latest · FY2025
(23.88M) CAD
Year-over-year change
+4.8%

Free Cash Flow vs competitors

How CRDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -4.0% is the 6th highest of 9, against a peer median of +28.8%.
  • Over three fiscal years its annual growth of -4.4% compares with a peer median of -7.0%.
CRDL Competitors
Free Cash Flow for CRDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMAImageneBio IncLTM Mar 2026$52.08M USD+36.1%-14.1%—
CNTBConnect Biopharma Holdings LimitedFY2025$51.64M USD+112.0%-20.7%80687.5%
KLRSKalaris Therapeutics IncLTM Mar 2026$49.09M USD—+64.1%—
IFRXInflaRx N.V.LTM Mar 2026€28.93M EUR-39.4%+0.1%98624.1%
HYPRHyperfine, Inc.LTM Mar 2026$28.66M USD-20.9%-26.4%187.0%
VANIVivani Medical, Inc.LTM Mar 2026$26.52M USD+21.6%+10.1%—
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$24.3M CAD-4.0%-4.4%—
MBOTMicrobot Medical Inc.LTM Mar 2026$15.38M USD+65.3%+4.1%14647.6%
INCRInterCure Ltd.LTM Jun 2025₪8.95M ILS+120.4%-25.0%3.7%
ASRTAssertio Holdings, Inc.LTM Mar 2026$7.08M USD-211.3%—6.9%
Peer median (excluding CRDL) —+28.8%-7.0%7417.3%

Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(31.64M)(30.93M)(28.13M)(36.68M)(33.82M)
Depreciation & Amortization220.42K219.91K248.36K373.11K101.98K
Deferred Income Tax(4.92M)(9.16M)000
Stock-Based Compensation8.5M5.01M4.16M14.28M10.7M
Change in Working Capital76.52K5.75M(545.88K)(931.57K)(733.34K)
Accounts Receivables(59.95K)(144.18K)200.33K(81.75K)135.43K
Inventory17.97K(4.47M)000
Accounts Payables2.39M4.47M000
Other Working Capital(2.27M)5.89M(746.2K)(849.82K)(868.76K)
Other Non-Cash Items4.21M1.89M(911.39K)(2.1M)(105.34K)
Operating Cash Flow(23.55M)(27.22M)(25.18M)(25.06M)(23.85M)
Capital Expenditures(12.92K)(74.71K)(64.31K)(21.29K)(24.48K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(12.92K)(74.71K)(64.31K)(21.29K)(24.48K)
Debt Repayment(51.92K)(53.93K)(55.38K)(41.53K)(55.38K)
Common Stock Issued84.08M0021.36M16.07M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.41M(0)0(2.47M)(477.03K)
Financing Cash Flow93.44M(53.93K)(55.38K)18.84M15.54M
Effect of Forex Changes(11.13K)2.92M762.04K1.89M(824.04K)
Net Change in Cash69.87M(24.43M)(24.54M)(4.35M)(9.16M)
Free Cash Flow(23.56M)(27.3M)(25.24M)(25.08M)(23.88M)

Cardiol Therapeutics Inc.

NASDAQ:CRDL

Intrinsic Alpha fair value

Locked

Current Price

$0.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.